Diabetes increases the risk of serious cardiac, cerebrovascular, and renal complications with major consequences on the quality of life of patients, while generating significant costs on our health care system. Using genomics information and artificial intelligence, a team of researchers from the CRCHUM, in collaboration with OPTITHERA, has developed the first genomic risk prediction test for patients with type 2 diabetes which are at risk of developping complications, well before the appearance of the first clinical signs. A better prediction of the risk of developing complications will allow early and personalized intervention in patients who are at high risk, and reduce anxiety and complications caused by overtreatment in those who are less at risk. A better prediction will also contribute to increased patient engagement in their own care.
This project aims to calibrate the test by taking into account the ethnic origin of the patient, and to develop the process of integrating genomic testing into the Quebec health system. The ultimate goal of the genomic risk prediction test is to “predict in order to prevent” for the benefit of diabetic patients as well as our health system.
Genome Centre: Génome Québec
User:
Pavel Hamet – OPTITHERA